The Kechuang Dream Factory has 20 GMP standard workshops, which house a total of 80 production lines. [Photo/ zj-toutiao]

Shanghai Tianci International Pharmaceutical signed cooperation agreements with Fosun Kite Biotechnology and Green Valley on Jan 17.

The cooperation marks the first pharmaceutical sharing platform in China, Kechuang Dream Factory, being officially put into operation.

Additionally, the industrialization of two major domestic innovative drugs, Fosun Kite’s Yescarta and Green Valley’s GV971, were settled in Zhangjiang science city.

The Kechuang Dream Factory is located in the south of Zhangjiang science city, covering an area of 211 mu (140,667 square meters), with a construction area of 280,000 square meters. It has 20 GMP (Good Manufacturing Practice) standard workshops, which house a total of 80 production lines.

According to Li Hanpu, chairman of Tianci International, most traditional pharmaceutical factories have a closed mindset and only produce their own drugs. They seldom conduct in cooperative activities and exchanges with other companies or institutions.

“To solve these problems, we built the world-class pharmaceutical sharing platform, which can improve the productivity and efficiency of the pharmaceutical industry and the conversion rate of innovative R&D results. Also it can reduce the comprehensive costs of the industry,” said Li.

Since China began the trail implementation of the Marketing Authorization Holder (MAH) in November 2015, the threshold and cost of the new drug’s industrialization have been greatly reduced.

By the end of November 2018, Pudong New Area had accepted 58 varieties of MAH applications submitted by 36 companies, among which 31 are Category One innovative drugs that have not been listed at home or abroad.